Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Novo Nordisk A/S ADR (NY: NVO )

131.22 +3.05 (+2.38%)
Streaming Delayed Price Updated: 9:50 AM EDT, Aug 9, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Novo Nordisk A/S ADR

< Previous 1 2
...
21 22 23 24 25 26 27 28 29
...
53 54 Next >
25% of Warren Buffett's Secret Portfolio Is Invested in These 3 ETFs. Here's Why They're Great Picks for 2024.
Buffett didn't personally pick these ETFs. But all three could make him money in the new year. 
Via The Motley Fool
Topics ETFs
3 Stock-Split Stocks With 51% to 128% Upside in 2024, According to Select Wall Street Analysts
Among Nvidia, Amazon, DexCom, Shopify, Alphabet, Tesla, Palo Alto Networks, Monster Beverage, and Novo Nordisk, there are three high-flying stocks a trio of Wall Street analysts believe can soar in the... 
Via The Motley Fool
If You Had Invested $10,000 in Novo Nordisk in 2018, This Is How Much You Would Have Today
Is it too late to invest in this fast-growing pharmaceutical company? 
Via The Motley Fool
Patients Regain Weight After They Quit Using Ozempic Rival Zepbound. Here's Why That Makes Eli Lilly Stock an Even Better Buy.
Lilly's weight loss drug appears to be on the way to becoming a megablockbuster. 
Via The Motley Fool
Despite its growth, NYSE:NVO remains within the realm of affordability.
NOVO-NORDISK A/S-SPONS ADR (NYSE:NVO) stands out as a growth opportunity that won't break the bank. 
Via Chartmill
Here's How Much You Would Have Made Owning Novo Nordisk Stock In The Last 10 Years
Via Benzinga
Weight-Loss Drug Gold Rush Gets Larger As New Player Fractyl Health Files For $100M IPO
Fractyl Health, developing procedural and gene therapies for type 2 diabetes and obesity, filed an S-1 filing with the SEC on Thursday to raise up to $100 million in an initial public offering. 
Via Benzinga
Topics Regulatory Compliance
Exposures Legal Regulatory
The New Magnificent 7: 7 Stocks Rising to Prominence
The next magnificent 7 stocks continue to rise to prominence and offer strong returns to investors and are generally stable. 
Via InvestorPlace
Ozempic Isn't the Best Weight-Loss Treatment Anymore. Here's Why That Shouldn't Matter to Novo Nordisk Investors.
Investors shouldn't be quick to discount Novo Nordisk's long-term potential. 
Via The Motley Fool
Ryan Cohen Plans to Save GameStop By Becoming Warren Buffett
Ryan Cohen's latest plan to save GME stock is transforming GameStop into Berkshire Hathaway. Will it work? 
Via InvestorPlace
3 Biotech Stocks With Promising Pipelines and Big Growth Potential in 2024
These biotech stocks with promising pipelines are showing some major promise and growth potential for the new year. 
Via InvestorPlace
Obesity Drugs: Employers Embrace Virtual Healthcare to Manage Surging Costs
U.S. 
Via Benzinga
Weight Loss Drugs' Trickle Down Effect - Insurer Restrictions Create Access Challenges For Diabetes Patients
There is growing concern among some type 2 diabetes patients over challenges in obtaining reimbursement for medications like Novo Nordisk A/S's (NYSE: NVO) Ozempic amid stricter health plan  
Via Benzinga
Better Growth Stock: Viking Therapeutics or Iovance Biotherapeutics?
Both of these pharma stocks could be big winners. But one stock screens as a better buy from a risk standpoint. 
Via The Motley Fool
Better Weight Loss Stock: Eli Lilly or Novo Nordisk?
Both of these pharma stocks have been top performers in 2023. One stock is the better long-term buy, however. 
Via The Motley Fool
What's Going On With Ozempic-Maker Novo Nordisk Stock?
Novo Nordisk A/S (NASDAQ: NVO) shares are moving Monday and the Ozempic-maker's stock has gained more than 40% year-to-date. 
Via Benzinga
Eli Lilly Skids, Weighing On Novo Nordisk, On A Key New Finding For Obesity Drugs
Researchers examined what happened after patients stopped taking Zepbound. 
Via Investor's Business Daily
Are These Biotechs Ready To Launch?
Biotech stocks are still in the process of repairing the damage from recent months — and recent years. Indeed, as of a month ago, the SPDR Biotech Fund had been dead money for an unbelievable eight and... 
Via Talk Markets
Bernie Sanders To Take On Ozempic, Wegovy, Weight Loss Drugs: 'Could Be Helpful, But They're Not Going To Be Helpful If People Can't Afford Them'
A hearing from the Senate led by Bernie Sanders will look at diabetes and the rise of weight loss drugs. 
Via Benzinga
Why Viking Therapeutics Was Crushing It This Week
Nowadays, it's good to be a developer of next-generation weight loss drugs. 
Via The Motley Fool
Could Eli Lilly Beat Novo Nordisk in the Billion-Dollar Weight Loss Market?
These drugs address a rapidly growing market. 
Via The Motley Fool
Zoetis Stock A Good Companion For Your Portfolio? Shares Rising
Reflecting strong fundamentals, Zoetis stock boasts a best-possible A SMR Rating (sales+profit margins+return on equity) on an A-to-E scale. 
Via Investor's Business Daily
JNJ CEO Signals No Rush Into Weight-Loss Drug Realm, Emphasizes Different Priorities
Johnson & Johnson (NYSE: JNJ) has no immediate plans to venture into weight-loss drugs due to the existing competition saturation, as Chief Executive Officer  
Via Benzinga
Obesity Drugs: Greater Weight Loss Linked to Prolonged Use of Novo Nordisk's Wegovy
A recent analysis of medical records and insurance claims data revealed that 40% of patients who received prescriptions for Novo Nordisk A/S's (NYSE: NVO) obesity treatment drug Wegovy in 2021 or 2022... 
Via Benzinga
Jim Cramer Highlights 'Transformational' Impact Of Weight Loss Drugs Like Ozempic: Focus Now On 'Potential Winners' From The Same Narrative
Via Benzinga
Roche, Pfizer Race To Find Next Ozempic As Pharma Giants Hustle To Join Obesity Treatment Market
Weight-loss drugs such as Ozempic and Mounjaro are the leading blockbusters for a new epidemic 
Via Benzinga
Roche Stock Rises On $3.1 Billion Deal For Obesity Drugmaker
Roche said it will spend up to $3.1 billion to acquire Carmot Therapeutics, a biotech firm developing obesity drugs. Roche stock gained on the news. 
Via Investor's Business Daily
Roche Joins Bandwagon To Challenge Novo Nordisk, Eli Lilly For Weight Loss Drugs
Roche Holding AG (OTC: RHHBY) has agreed to 
Via Benzinga
1 Stock-Split Stock to Buy Hand Over Fist in December, and 1 to Avoid Like the Plague
Among Nvidia, Amazon, DexCom, Shopify, Alphabet, Tesla, Palo Alto Networks, Monster Beverage, and Novo Nordisk, there's a historically cheap outperformer, as well as an industry leader that could... 
Via The Motley Fool
3 No-Brainer Growth Stocks to Buy in December
No analysis paralysis is required with these great stocks. 
Via The Motley Fool
< Previous 1 2
...
21 22 23 24 25 26 27 28 29
...
53 54 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.